49464 Federal Register / Vol. 71, No.
163 / Wednesday, August 23, 2006 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Aging.
Date: September 26–27, 2006.
Closed: September 26, 2006, 3 p.m. to 5
p.m.
Agenda: To review and evaluate grant
applications and or proposals.
Place: National Institutes of Health,
Building 31, Conference Room 10, 9000
Rockville Pike, Bethesda, MD 20892.
Open: September 27, 2006, 8 a.m. to 1:30
p.m.
Agenda: Call to Order, Task Force on
Minority Aging Report; Working Group on
Program Report; Geriatrics and Clinical
Gerontology Program Review Report; and
Program Highlights.
Place: National Institutes of Health,
Building 31, Conference Room 10, 9000
Rockville Pike, Bethesda, MD 20892.
Contact Person: Robin Barr, PhD, Acting
Director, Office of Extramural Affairs,
National Institute on Aging, 7201 Wisconsin
Avenue, Gateway Bldg., Suite 2C218,
Bethesda, MD 20814, 301–496–9322.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
sroberts on PROD1PC70 with NOTICES
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
VerDate Aug<31>2005 16:04 Aug 22, 2006 Jkt 208001
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: http://
www.nih.gov/nia/naca/, where agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS).
Dated: August 15, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7083 Filed 8–22–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal infromation concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Tropical Microbicide Safety
and Efficacy Evaluation in Nonhuman
Primates.
Date: September 12, 2006.
Time: 10 a.m. to 4 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817; (Telephone Conference
Call).
Contact Person: Lynn Rust, PhD, Scientific
Review Administrator, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892; (301) 402–3938; lr228v@nih.gov
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\23AUN1.SGM
Emphasis Panel, Unsolicited Immunology
Program Project Application.
Date: September 12, 2006.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Room 3123, Bethesda, MD 20892; (Telephone
Conference Call).
Contact Person: Alec Ritchie, PhD,
Scientific Review Administrator, DHHS/NIH/
NIAID/DEA Scientific Review Program,
6700B Rockledge Drive MSC 7616, Room
3123, Bethesda, MD 20892; 301–496–2550;
aritchie@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Review of Clinical Trial and
Implementation Grants.
Date: September 13, 2006.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Gaithersburg Marriott
Washingtonian Center, 9751 Washingtonian
Boulevard, Gaithersburg, MD 20878.
Contact Person: Quirijn Vos, PhD,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B
Rockledge Drive MSC 7616, Bethesda, MD
20892; 301–451–2666; qvos@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS).
Dated: August 15, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7084 Filed 8–22–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
23AUN1
 Federal Register / Vol. 71, No. 163 / Wednesday, August 23, 2006 / Notices
Name of Committee: National Institute on
Aging Special Emphasis Panel, Reproductive
Hormones and the Brain I.
Date: September 6, 2006.
Time: 11 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
2C212, Bethesda, MD 20814, (Telephone
Conference Call).
Contact Person: Bita Nakhai, PhD,
Scientific Review Administrator, Scientific
Review Office, National Institute on Aging,
Gateway Bldg., 2C212, 7201 Wisconsin
Avenue, Bethesda, MD 20814, 301–402–
7701, nakhaib@nia.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Aging Special Emphasis Panel, Genes
Responsible for Prolonged Existence I.
Date: September 21, 2006.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20817, (Telephone Conference
Call).
Contact Person: Bita Nakhai, PhD,
Scientific Review Administrator, Scientific
Review Office, National Institute on Aging,
Gateway Bldg., 2C212, 7201 Wisconsin
Avenue, Bethesda, MD 20814, 301–402–
7701, nakhaib@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: August 15, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7085 Filed 8–22–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive
License: Method for Diagnosis of
Atherosclerosis
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of a worldwide
sroberts on PROD1PC70 with NOTICES
co-exclusive license to practice the
invention embodied in: PCT
Application No. US2005/031469 filed 9/
2/2005, titled ‘‘Method for Diagnosis of
Atherosclerosis’’ referenced at DHHS as
VerDate Aug<31>2005 16:04 Aug 22, 2006 Jkt 208001
E–276–2004/2–PCT–01 to Ortho-
Clinical Diagnostics, Inc., having a place
of business in the state of New Jersey.
The field of use may be limited to an
FDA approved clinical diagnostic
product for atherosclerosis. The United
States of America is the assignee of the
patent rights in this invention. The
territory may be worldwide. This
announcement is the second Notice to
grant a license to this technology. The
initial Notice was published in 70 FR
39525, July 8, 2005.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
October 23, 2006 will be considered.
ADDRESSES: Requests for a copy of the
patent applications, inquiries,
comments and other materials relating
to the contemplated license should be
directed to: Fatima Sayyid, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
telephone: (301) 435–4521; facsimile:
(301) 402–0220; e-mail:
sayyidf@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
subject PCT application is related to the
field of vascular disease and biomarkers
FOS and DUSP1 as expressed in
peripheral blood or secreted into serum.
The prospective co-exclusive license
will be royalty-bearing and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The
prospective co-exclusive license may be
granted unless, within 60 days from the
date of this published Notice, NIH
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: August 15, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–13935 Filed 8–22–06; 8:45 am]
BILLING CODE 4140–01–P
PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 E:\FR\FM\23AUN1.SGM
49465
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Treatment of Proliferative
Disorders Using an Unexpected mTOR
Kinase Inhibitor
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
(a)(1)(i), that the National Institutes of
Health (NIH), Department of Health and
Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the invention
embodied in: PCT patent application
PCT/US2004/041256 filed December 9,
2004, entitled: ‘‘Methods for
Suppressing an Immune Response or
Treating a Proliferative Disorder’’ [HHS
Reference Number: E–259–2003/0–PCT–
02], to Sahajanand Medical
Technologies Pvt. Ltd., registered as a
private limited company in accordance
with the Companies Act of India, having
a principle place of business in Surat,
India and U.S. headquarters in
Gaithersburg, Maryland. The field of use
may be limited to the use of 2-(4-
piperazinyl)-8-phenyl-4H-1-benzopyran-
4-one (LY303511), for the treatment and
prevention of stenosis and restenosis
and/or other proliferative disorders. The
United States of America is an assignee
of the patent rights in these inventions.
This notice replaces a notice
published in 71 FR 46496, August 14,
2006, to correct the heading
‘‘Prospective Grant of Exclusive License:
Treatment of Cardiovascular Conditions
with Nitrite Therapy’’ to read
‘‘Prospective Grant of Exclusive License:
Treatment of Proliferative Disorders
Using an Unexpected mTOR Kinase
Inhibitor’’.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
October 13, 2006 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Susan Carson, D.Phil., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804; e-
mail: carsonsu@od.nih.gov; telephone:
(301) 435–5020; facsimile: (301) 402–
0220.
SUPPLEMENTARY INFORMATION: The
search for specific kinase inhibitors is
23AUN1